Tag: press

SINGAPORE, June 13, 2025 (GLOBE NEWSWIRE) -- Multi Ways Holdings Limited (“Multi Ways,” the “Company” or the “Issuer”) (NYSE American: MWG), a leading supplier of a wide range of heavy construction equipment for sales and rental in Singapore and the surrounding region, announced that it has filed its annual report on Form 20-F, including its financial results, for the fiscal year ended December 31, 2024 (the “2024 Annual Report”) with the U.S. Securities and Exchange Commission. The 2024 Annual Report can be accessed under the “Investor Relations” section of the Company’s investor relations website at www.multiwaysholdings.com.

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

Millicom (Tigo) Announces Partial Closing of Infrastructure Deal with SBA and Intention to Declare a Special Dividend of $2.50 per Share Representing Around 45% of the Proceeds

URUMQI, China, June 13, 2025 (GLOBE NEWSWIRE) -- Chanson International Holding (Nasdaq: CHSN) (the “Company” or “Chanson”), a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, today announced that it has priced a best-efforts public offering with gross proceeds to the Company expected to be approximately $8 million, before deducting placement agent fees and other estimated expenses payable by the Company, excluding the exercise of any warrant offered.

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE^® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard^® Prime EPS.